The US Food and Drug Administration office that oversees gene and cell therapies is piloting a series of measures aimed at improving communications and providing clearer and more consistent advice to sponsors, especially when it comes to written responses.
These “pilot solutions” include better leveraging the agency’s website to improve sponsor engagement with the Office of Tissues and Advanced...








